Deals In Depth: December 2013
Executive Summary
Following the loss of patent protection on its antidepressant Lexapro in 2012, Forest added a new drug to its neurology portfolio, licensing US rights to Merck’s antipsychotic Saphris for $240 million; AstraZeneca took full control of BMS’s global diabetes business, paying $2.9 billion up front. Financing in December lagged behind the previous month’s figures in both biopharma and device.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.